세계의 라베프라졸 나트륨 시장 : 규모, 점유율, 동향 분석 보고서 - 연령별, 유통 채널별, 용도별, 지역별 전망과 예측(2024-2031년)
Global Rabeprazole Sodium Market Size, Share & Trends Analysis Report By Age, By Distribution Channel (Drug & Retail Store Pharmacies, Hospital Pharmacies and Online Pharmacies), By Application, By Regional Outlook and Forecast, 2024 - 2031
상품코드:1511396
리서치사:KBV Research
발행일:2024년 06월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
라베프라졸 나트륨 시장 규모는 예측 기간 동안 3.7%의 복합 연간 성장률(CAGR)로 성장하여 2031년까지 8억 4,530만 달러에 달할 것으로 예상되고 있습니다.
게다가 의약품 제형과 약물 전달 시스템의 혁신은 라베프라졸 나트륨의 효능과 환자의 컴플라이언스를 크게 향상시키고 위장 장애의 치료의 기초로서의 지위를 확립했습니다. 따라서 의약품 제형과 약물 전달 시스템의 지속적인 혁신으로 시장 상황이 변했습니다.
그러나 일부 연구에 따르면 위산의 억제가 장기간 지속되면 뼈 건강에 중요한 칼슘의 흡수를 방해할 수 있다고 합니다. 칼슘 흡수가 감소하면 뼈의 미네랄 밀도가 정상보다 낮아지고, 특히 손목, 척추 및 고관절의 골절 위험이 높아집니다. 따라서, 이러한 모든 우려가 이 보충제의 도입을 방해할 수 있습니다.
유행과 관련된 과제를 해결하기 위해 의료 제공 모델을 적응시켜 원격 의료 서비스와 원격 환자 모니터링의 혁신을 촉진했습니다. 원격 의료는 만성 위장 질환을 관리하고 잠김 및 사회적 거리 확보 조치 기간 동안 노출 위험을 최소화하면서 관리 연속성을 보장하기위한 실행 가능한 옵션으로 부상했습니다. 따라서 유행은 시장에 전반적으로 부정적인 영향을 미쳤습니다.
연령별 전망입니다.
나이에 따라 시장은 55세 미만과 55세 이상으로 분류됩니다. 55세 미만의 부문은 2023년 시장에서 67.9%의 수익 점유율을 획득했습니다. 이 인구통계에는 위식도 역류증(GERD), 소화성 궤양 및 기타 산 관련 위장 장애의 영향을 받는 젊은 성인과 중년 개인이 포함됩니다.
유통 채널별 전망입니다.
유통 채널별로 볼 때 시장은 병원 약국, 약국 및 소매점 약국, 온라인 공급자로 나뉘어져 있습니다. 병원 약국 부문은 2023년 시장에서 24%의 수익 점유율을 획득했습니다. 병원 약국은 의료 현장에 필수적인 존재이며 특수한 의약품 요구를 가진 입원 환자와 외래 환자에 대응하고 있습니다.
용도별 전망입니다.
용도에 따라 시장은 위식도 역류, 소화성 궤양 등으로 분류됩니다. 위식도 역류증 부문은 2023년 시장에서 58.3%의 수익 점유율을 획득했습니다. 흉통, 역류, 가슴앓이는 위산이 식도로 역류하는 만성 소화기 질환 인 GERD와 관련된 증상의 일부입니다.
지역별 전망입니다.
지역별로 보면 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동, 아프리카에 걸쳐 분석되고 있습니다. 아시아태평양의 부문은 2023년 시장에서 25.5%의 수익 점유율을 획득했습니다. 이 지역에는 도시화, 식습관 변화, 라이프스타일 변화로 위장장애가 증가하고 있는 중국, 인도, 일본 등 급속히 성장하는 경제가 포함됩니다.
목차
제1장 시장 범위와 조사 방법
시장의 정의
목적
시장 범위
세분화
조사 방법
제2장 시장 요람
주요 하이라이트
제3장 시장 개요
소개
개요
시장구성과 시나리오
시장에 영향을 미치는 주요 요인
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
시장의 과제
Porter's Five Forces 분석
제4장 시장 : 연령별
세계 55세 이하 시장 : 지역별
세계 55세 이상 시장 : 지역별
제5장 시장 : 유통 채널별
세계 약국 및 약국 시장 : 지역별
세계 병원 약국 시장 : 지역별
세계 온라인 약국 시장 : 지역별
제6장 시장 : 용도별
세계 위식도 역류증 시장 : 지역별
세계 소화성 궤양 시장 : 지역별
세계 기타 시장 : 지역별
제7장 시장 : 지역별
북미
북미 시장 : 국가별
미국
캐나다
멕시코
기타 북미
유럽
유럽 시장 : 국가별
독일
영국
프랑스
러시아
스페인
이탈리아
기타 유럽
아시아태평양
아시아태평양 시장 : 국가별
중국
일본
인도
한국
싱가포르
말레이시아
기타 아시아태평양
라틴아메리카, 중동, 아프리카
라틴아메리카, 중동, 아프리카 시장 : 국가별
브라질
아르헨티나
아랍에미리트(UAE)
사우디아라비아
남아프리카
나이지리아
기타 라틴아메리카, 중동, 아프리카
제8장 기업 프로파일
Cadila Pharmaceutical Limited
Alembic Pharmaceuticals Ltd(Alembic Group)
Woodward Pharma Services
Elikem Pharmaceuticals Pvt Ltd.
Jasco Labs Pvt Ltd
Torrent Pharmaceuticals Ltd
Cipla Limited
Sun Pharmaceutical Industries Ltd
Intas Pharmaceutical Ltd
Dr Reddy's Laboratories Ltd.
제9장 라베프라졸 나트륨 시장의 성공 필수 조건
BJH
영문 목차
영문목차
The Global Rabeprazole Sodium Market size is expected to reach $845.3 million by 2031, rising at a market growth of 3.7% CAGR during the forecast period.
Several factors contribute to this dominance, such as the high incidence of peptic ulcers and gastroesophageal reflux disease (GERD) in the general population. Additionally, the region boasts a well-established healthcare infrastructure, extensive insurance coverage, and high healthcare spending, facilitating access to advanced gastrointestinal treatments. The market growth of North America is further supported by the presence of prominent pharmaceutical companies and ongoing research and development initiatives. Thus, the North America region acquired 40.5% revenue share in the market 2023.
GERD is one of the most common gastrointestinal disorders. It is distinguished by the reflux of gastric acid into the esophagus, which results in symptoms such as regurgitation, chest pain, and heartburn. According to the National Library of Medicine, GERD impacts up to 20% of the adult population in Western countries.
Additionally, Innovations in pharmaceutical formulations and drug delivery systems have significantly enhanced rabeprazole sodium's efficacy and patient compliance, positioning it as a cornerstone in treating gastrointestinal disorders. Therefore, the continuous innovation in pharmaceutical formulations and drug delivery systems has transformed the market landscape.
However, several studies have indicated that prolonged suppression of stomach acid can interfere with calcium absorption, which is critical for bone health. This reduction in calcium absorption may lead to a density of bone minerals that is less than normal, which in turn elevates the risk of fractures, notably in the wrist, spine, and hip. Hence, all these concerns may impede the adoption of it.
Adapting healthcare delivery models to accommodate pandemic-related challenges fostered innovation in telehealth services and remote patient monitoring. Telemedicine emerged as a viable option for managing chronic gastrointestinal conditions, ensuring continuity of care while minimizing exposure risks during periods of lockdowns and social distancing measures. Hence, the pandemic had an overall negative impact on the market.
Age Outlook
On the basis of age, the market is classified into below 55 years and above 55 years. The below 55 years segment acquired 67.9% revenue share in the market in 2023. This demographic includes younger adults and middle-aged individuals who are increasingly affected by gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders.
Distribution Channel Outlook
By distribution channel, the market is divided into hospital pharmacies, drug & retail store pharmacies, and online providers. The hospital pharmacies segment garnered 24% revenue share in the market in 2023. Hospital pharmacies are integral to healthcare settings, catering to inpatients and outpatients with specialized pharmaceutical needs.
Application Outlook
Based on application, the market is characterized into gastroesophageal reflux disease, peptic ulcer, and others. The gastroesophageal reflux disease segment garnered 58.3% revenue share in the market in 2023. Chest pain, regurgitation, and heartburn are some of the symptoms associated with GERD, which is a chronic digestive ailment that is characterized by the reflux of gastric acid into the esophagus.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 25.5% revenue share in the market in 2023. This region encompasses rapidly growing economies such as China, India, and Japan, where gastrointestinal disorders are increasing due to urbanization, changing dietary habits, and lifestyle modifications.
List of Key Companies Profiled
Cipla Limited
Sun Pharmaceutical Industries Ltd.
Intas Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd.
Cadila Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd
Woodward Pharma
Elikem Pharmaceuticals Pvt Ltd
Jasco Labs Private Limited
Torrent Pharmaceuticals Ltd.
Global Rabeprazole Sodium Market Report Segmentation
By Age
Below 55 years and
Above 55 years
By Distribution Channel
Drug & Retail Store Pharmacies,
Hospital Pharmacies and
Online Pharmacies
By Application
Gastroesophageal Reflux Disease,
Peptic Ulcer and
Others
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Rabeprazole Sodium Market, by Age
1.4.2 Global Rabeprazole Sodium Market, by Distribution Channel
1.4.3 Global Rabeprazole Sodium Market, by Application
1.4.4 Global Rabeprazole Sodium Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Global Rabeprazole Sodium Market by Age
4.1 Global Below 55 years Market by Region
4.2 Global Above 55 years Market by Region
Chapter 5. Global Rabeprazole Sodium Market by Distribution Channel
5.1 Global Drug & Retail Store Pharmacies Market by Region
5.2 Global Hospital Pharmacies Market by Region
5.3 Global Online Pharmacies Market by Region
Chapter 6. Global Rabeprazole Sodium Market by Application
6.1 Global Gastroesophageal Reflux Disease Market by Region
6.2 Global Peptic Ulcer Market by Region
6.3 Global Others Market by Region
Chapter 7. Global Rabeprazole Sodium Market by Region
7.1 North America Rabeprazole Sodium Market
7.1.1 North America Rabeprazole Sodium Market by Age
7.1.1.1 North America Below 55 years Market by Country
7.1.1.2 North America Above 55 years Market by Country
7.1.2 North America Rabeprazole Sodium Market by Distribution Channel
7.1.2.1 North America Drug & Retail Store Pharmacies Market by Country
7.1.2.2 North America Hospital Pharmacies Market by Country
7.1.2.3 North America Online Pharmacies Market by Country
7.1.3 North America Rabeprazole Sodium Market by Application
7.1.3.1 North America Gastroesophageal Reflux Disease Market by Country
7.1.3.2 North America Peptic Ulcer Market by Country
7.1.3.3 North America Others Market by Country
7.1.4 North America Rabeprazole Sodium Market by Country
7.1.4.1 US Rabeprazole Sodium Market
7.1.4.1.1 US Rabeprazole Sodium Market by Age
7.1.4.1.2 US Rabeprazole Sodium Market by Distribution Channel
7.1.4.1.3 US Rabeprazole Sodium Market by Application
7.1.4.2 Canada Rabeprazole Sodium Market
7.1.4.2.1 Canada Rabeprazole Sodium Market by Age
7.1.4.2.2 Canada Rabeprazole Sodium Market by Distribution Channel
7.1.4.2.3 Canada Rabeprazole Sodium Market by Application
7.1.4.3 Mexico Rabeprazole Sodium Market
7.1.4.3.1 Mexico Rabeprazole Sodium Market by Age
7.1.4.3.2 Mexico Rabeprazole Sodium Market by Distribution Channel
7.1.4.3.3 Mexico Rabeprazole Sodium Market by Application
7.1.4.4 Rest of North America Rabeprazole Sodium Market
7.1.4.4.1 Rest of North America Rabeprazole Sodium Market by Age
7.1.4.4.2 Rest of North America Rabeprazole Sodium Market by Distribution Channel
7.1.4.4.3 Rest of North America Rabeprazole Sodium Market by Application
7.2 Europe Rabeprazole Sodium Market
7.2.1 Europe Rabeprazole Sodium Market by Age
7.2.1.1 Europe Below 55 years Market by Country
7.2.1.2 Europe Above 55 years Market by Country
7.2.2 Europe Rabeprazole Sodium Market by Distribution Channel
7.2.2.1 Europe Drug & Retail Store Pharmacies Market by Country
7.2.2.2 Europe Hospital Pharmacies Market by Country
7.2.2.3 Europe Online Pharmacies Market by Country
7.2.3 Europe Rabeprazole Sodium Market by Application
7.2.3.1 Europe Gastroesophageal Reflux Disease Market by Country
7.2.3.2 Europe Peptic Ulcer Market by Country
7.2.3.3 Europe Others Market by Country
7.2.4 Europe Rabeprazole Sodium Market by Country
7.2.4.1 Germany Rabeprazole Sodium Market
7.2.4.1.1 Germany Rabeprazole Sodium Market by Age
7.2.4.1.2 Germany Rabeprazole Sodium Market by Distribution Channel
7.2.4.1.3 Germany Rabeprazole Sodium Market by Application
7.2.4.2 UK Rabeprazole Sodium Market
7.2.4.2.1 UK Rabeprazole Sodium Market by Age
7.2.4.2.2 UK Rabeprazole Sodium Market by Distribution Channel
7.2.4.2.3 UK Rabeprazole Sodium Market by Application
7.2.4.3 France Rabeprazole Sodium Market
7.2.4.3.1 France Rabeprazole Sodium Market by Age
7.2.4.3.2 France Rabeprazole Sodium Market by Distribution Channel
7.2.4.3.3 France Rabeprazole Sodium Market by Application
7.2.4.4 Russia Rabeprazole Sodium Market
7.2.4.4.1 Russia Rabeprazole Sodium Market by Age
7.2.4.4.2 Russia Rabeprazole Sodium Market by Distribution Channel
7.2.4.4.3 Russia Rabeprazole Sodium Market by Application
7.2.4.5 Spain Rabeprazole Sodium Market
7.2.4.5.1 Spain Rabeprazole Sodium Market by Age
7.2.4.5.2 Spain Rabeprazole Sodium Market by Distribution Channel
7.2.4.5.3 Spain Rabeprazole Sodium Market by Application
7.2.4.6 Italy Rabeprazole Sodium Market
7.2.4.6.1 Italy Rabeprazole Sodium Market by Age
7.2.4.6.2 Italy Rabeprazole Sodium Market by Distribution Channel
7.2.4.6.3 Italy Rabeprazole Sodium Market by Application
7.2.4.7 Rest of Europe Rabeprazole Sodium Market
7.2.4.7.1 Rest of Europe Rabeprazole Sodium Market by Age
7.2.4.7.2 Rest of Europe Rabeprazole Sodium Market by Distribution Channel
7.2.4.7.3 Rest of Europe Rabeprazole Sodium Market by Application
7.3 Asia Pacific Rabeprazole Sodium Market
7.3.1 Asia Pacific Rabeprazole Sodium Market by Age
7.3.1.1 Asia Pacific Below 55 years Market by Country
7.3.1.2 Asia Pacific Above 55 years Market by Country
7.3.2 Asia Pacific Rabeprazole Sodium Market by Distribution Channel
7.3.2.1 Asia Pacific Drug & Retail Store Pharmacies Market by Country
7.3.2.2 Asia Pacific Hospital Pharmacies Market by Country
7.3.2.3 Asia Pacific Online Pharmacies Market by Country
7.3.3 Asia Pacific Rabeprazole Sodium Market by Application
7.3.3.1 Asia Pacific Gastroesophageal Reflux Disease Market by Country
7.3.3.2 Asia Pacific Peptic Ulcer Market by Country
7.3.3.3 Asia Pacific Others Market by Country
7.3.4 Asia Pacific Rabeprazole Sodium Market by Country
7.3.4.1 China Rabeprazole Sodium Market
7.3.4.1.1 China Rabeprazole Sodium Market by Age
7.3.4.1.2 China Rabeprazole Sodium Market by Distribution Channel
7.3.4.1.3 China Rabeprazole Sodium Market by Application
7.3.4.2 Japan Rabeprazole Sodium Market
7.3.4.2.1 Japan Rabeprazole Sodium Market by Age
7.3.4.2.2 Japan Rabeprazole Sodium Market by Distribution Channel
7.3.4.2.3 Japan Rabeprazole Sodium Market by Application
7.3.4.3 India Rabeprazole Sodium Market
7.3.4.3.1 India Rabeprazole Sodium Market by Age
7.3.4.3.2 India Rabeprazole Sodium Market by Distribution Channel
7.3.4.3.3 India Rabeprazole Sodium Market by Application
7.3.4.4 South Korea Rabeprazole Sodium Market
7.3.4.4.1 South Korea Rabeprazole Sodium Market by Age
7.3.4.4.2 South Korea Rabeprazole Sodium Market by Distribution Channel
7.3.4.4.3 South Korea Rabeprazole Sodium Market by Application
7.3.4.5 Singapore Rabeprazole Sodium Market
7.3.4.5.1 Singapore Rabeprazole Sodium Market by Age
7.3.4.5.2 Singapore Rabeprazole Sodium Market by Distribution Channel
7.3.4.5.3 Singapore Rabeprazole Sodium Market by Application
7.3.4.6 Malaysia Rabeprazole Sodium Market
7.3.4.6.1 Malaysia Rabeprazole Sodium Market by Age
7.3.4.6.2 Malaysia Rabeprazole Sodium Market by Distribution Channel
7.3.4.6.3 Malaysia Rabeprazole Sodium Market by Application
7.3.4.7 Rest of Asia Pacific Rabeprazole Sodium Market
7.3.4.7.1 Rest of Asia Pacific Rabeprazole Sodium Market by Age
7.3.4.7.2 Rest of Asia Pacific Rabeprazole Sodium Market by Distribution Channel
7.3.4.7.3 Rest of Asia Pacific Rabeprazole Sodium Market by Application
7.4 LAMEA Rabeprazole Sodium Market
7.4.1 LAMEA Rabeprazole Sodium Market by Age
7.4.1.1 LAMEA Below 55 years Market by Country
7.4.1.2 LAMEA Above 55 years Market by Country
7.4.2 LAMEA Rabeprazole Sodium Market by Distribution Channel
7.4.2.1 LAMEA Drug & Retail Store Pharmacies Market by Country
7.4.2.2 LAMEA Hospital Pharmacies Market by Country
7.4.2.3 LAMEA Online Pharmacies Market by Country
7.4.3 LAMEA Rabeprazole Sodium Market by Application
7.4.3.1 LAMEA Gastroesophageal Reflux Disease Market by Country
7.4.3.2 LAMEA Peptic Ulcer Market by Country
7.4.3.3 LAMEA Others Market by Country
7.4.4 LAMEA Rabeprazole Sodium Market by Country
7.4.4.1 Brazil Rabeprazole Sodium Market
7.4.4.1.1 Brazil Rabeprazole Sodium Market by Age
7.4.4.1.2 Brazil Rabeprazole Sodium Market by Distribution Channel
7.4.4.1.3 Brazil Rabeprazole Sodium Market by Application
7.4.4.2 Argentina Rabeprazole Sodium Market
7.4.4.2.1 Argentina Rabeprazole Sodium Market by Age
7.4.4.2.2 Argentina Rabeprazole Sodium Market by Distribution Channel
7.4.4.2.3 Argentina Rabeprazole Sodium Market by Application
7.4.4.3 UAE Rabeprazole Sodium Market
7.4.4.3.1 UAE Rabeprazole Sodium Market by Age
7.4.4.3.2 UAE Rabeprazole Sodium Market by Distribution Channel
7.4.4.3.3 UAE Rabeprazole Sodium Market by Application
7.4.4.4 Saudi Arabia Rabeprazole Sodium Market
7.4.4.4.1 Saudi Arabia Rabeprazole Sodium Market by Age
7.4.4.4.2 Saudi Arabia Rabeprazole Sodium Market by Distribution Channel
7.4.4.4.3 Saudi Arabia Rabeprazole Sodium Market by Application
7.4.4.5 South Africa Rabeprazole Sodium Market
7.4.4.5.1 South Africa Rabeprazole Sodium Market by Age
7.4.4.5.2 South Africa Rabeprazole Sodium Market by Distribution Channel
7.4.4.5.3 South Africa Rabeprazole Sodium Market by Application
7.4.4.6 Nigeria Rabeprazole Sodium Market
7.4.4.6.1 Nigeria Rabeprazole Sodium Market by Age
7.4.4.6.2 Nigeria Rabeprazole Sodium Market by Distribution Channel
7.4.4.6.3 Nigeria Rabeprazole Sodium Market by Application
7.4.4.7 Rest of LAMEA Rabeprazole Sodium Market
7.4.4.7.1 Rest of LAMEA Rabeprazole Sodium Market by Age
7.4.4.7.2 Rest of LAMEA Rabeprazole Sodium Market by Distribution Channel
7.4.4.7.3 Rest of LAMEA Rabeprazole Sodium Market by Application
Chapter 8. Company Profiles
8.1 Cadila Pharmaceutical Limited
8.1.1 Company Overview
8.2 Alembic Pharmaceuticals Ltd. (Alembic Group)
8.2.1 Company Overview
8.3 Woodward Pharma Services
8.3.1 Company Overview
8.4 Elikem Pharmaceuticals Pvt. Ltd.
8.4.1 Company Overview
8.5 Jasco Labs Pvt Ltd
8.5.1 Company Overview
8.6 Torrent Pharmaceuticals Ltd.
8.6.1 Company Overview
8.7 Cipla Limited
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Sun Pharmaceutical Industries Ltd.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 SWOT Analysis
8.9 Intas Pharmaceutical Ltd.
8.9.1 Company Overview
8.10. Dr. Reddy's Laboratories Ltd.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis
Chapter 9. Winning Imperatives of Rabeprazole Sodium Market